Insigneo Advisory Services LLC Boosts Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Insigneo Advisory Services LLC lifted its position in Becton, Dickinson and Company (NYSE:BDX) by 19.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,760 shares of the medical instruments supplier’s stock after purchasing an additional 608 shares during the quarter. Insigneo Advisory Services LLC’s holdings in Becton, Dickinson and Company were worth $861,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC lifted its stake in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Becton, Dickinson and Company by 56.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 45,792 shares of the medical instruments supplier’s stock valued at $10,371,000 after purchasing an additional 16,537 shares during the period. Van ECK Associates Corp lifted its position in Becton, Dickinson and Company by 3.1% during the fourth quarter. Van ECK Associates Corp now owns 14,738 shares of the medical instruments supplier’s stock valued at $3,344,000 after purchasing an additional 450 shares during the period. Sierra Ocean LLC purchased a new stake in Becton, Dickinson and Company in the fourth quarter valued at $29,000. Finally, Americana Partners LLC grew its position in Becton, Dickinson and Company by 3.5% during the 4th quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier’s stock worth $345,000 after purchasing an additional 52 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 1.2%

Shares of NYSE:BDX opened at $170.01 on Wednesday. The business’s 50 day moving average price is $181.67 and its 200-day moving average price is $212.31. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm has a market capitalization of $48.73 billion, a price-to-earnings ratio of 32.45, a price-to-earnings-growth ratio of 1.30 and a beta of 0.25. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The business had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.35 billion. During the same period last year, the firm posted $3.17 earnings per share. The company’s revenue was up 4.5% compared to the same quarter last year. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, June 9th. This represents a $4.16 annualized dividend and a yield of 2.45%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 79.39%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 479 shares of the firm’s stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the transaction, the executive vice president now directly owns 4,887 shares of the company’s stock, valued at approximately $964,107.36. This trade represents a 8.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP David Shan sold 1,166 shares of the business’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president now owns 4,575 shares in the company, valued at $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BDX. Wells Fargo & Company cut Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a report on Thursday, May 1st. Piper Sandler downgraded Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $260.00 to $185.00 in a report on Friday, May 2nd. Barclays dropped their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 3rd. Morgan Stanley decreased their target price on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating for the company in a research note on Tuesday, May 6th. Finally, Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $219.22.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.